Susana Correia

Company: Dyne Therapeutics

Job title: Director, Neuromuscular Research

Seminars:

TfR1-Mediated Delivery of Oligonucleotides and Enzymes to Address Neuromuscular Diseases: Translating Research into Functional Improvement in the Clinic 12:00 pm

The FORCE™ platform leverages Transferrin Receptor 1 (TfR1) to enable delivery of therapeutic oligonucleotides and enzymes to muscle and the CNS Preclinical data in models of DM1, DMD and Pompe diseases demonstrate that the FORCE platform delivers broad functional improvement in muscle and CNS The FORCE platform achieved POC in the ACHIEVE and DELIVER trials in DM1 and DMD, demonstrating…Read more

day: Day Two - Morning - Track A